The Use of N-acetylcysteine Supplementation to Decrease Irritability in Four Youths With Autism Spectrum Disorders.

Children and adolescents with autism spectrum disorder (ASD) often experience high levels of irritability, which adversely affects their functioning and behaviors. N-acetylcysteine (NAC), an antioxidant precursor to glutathione, has recently been studied for a variety of neuropsychiatric disorders. There is growing evidence to support its use to decrease irritability and self-injurious behaviors in youth with ASD. However, previous studies were limited to outpatient youth with mild symptoms of irritability, maintained on stable medication regimens, who do not meet criteria for higher levels of care. We describe the use of NAC among 4 youths (14-17 years) with ASD who had Aberrant Behavior Checklist-Irritability (ABC-I) scores of ≥ 20 and other psychotropic medication trials prior to treatment with NAC. In all of the cases, NAC appeared to be well tolerated. There was a reduction of symptoms of irritability and/or antipsychotic medication dosages in these cases; despite this, the authors cannot know whether use of NAC or other medication or behavioral strategies were responsible for such changes because this study was not a controlled trial.

[1]  M. Mazurek,et al.  Psychometric characteristics of the aberrant behavior checklist in a well-defined sample of youth with autism Spectrum disorder , 2019, Research in Autism Spectrum Disorders.

[2]  B. Tonge,et al.  A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder , 2017, The Australian and New Zealand journal of psychiatry.

[3]  C. McDougle,et al.  A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder , 2016, Molecular Autism.

[4]  J. Dopheide,et al.  Acetylcysteine for treatment of autism spectrum disorder symptoms. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  M. Mohammadi,et al.  N-Acetylcysteine as an Adjunctive Therapy to Risperidone for Treatment of Irritability in Autism: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety , 2015, Clinical neuropharmacology.

[6]  J. Veenstra-VanderWeele,et al.  N-acetylcysteine as treatment for self-injurious behavior in a child with autism. , 2014, Journal of child and adolescent psychopharmacology.

[7]  A. Ghanizadeh,et al.  A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders , 2013, BMC Psychiatry.

[8]  A. Hardan,et al.  A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with Autism , 2012, Biological Psychiatry.

[9]  S. Patten,et al.  Metabolic and Neurological Complications of Second-Generation Antipsychotic Use in Children , 2011, Drug safety.

[10]  Aubyn C. Stahmer,et al.  Psychotropic Medication Use Among Medicaid-Enrolled Children With Autism Spectrum Disorders , 2008, Pediatrics.

[11]  Janet K. Kern,et al.  Evidence of Toxicity, Oxidative Stress, and Neuronal Insult in Autism , 2006, Journal of toxicology and environmental health. Part B, Critical reviews.

[12]  Zheng-Xiong Xi,et al.  The Origin and Neuronal Function of In Vivo Nonsynaptic Glutamate , 2002, The Journal of Neuroscience.